A UK pharmaceutical company wishing to increase its portfolio of speciality generics, was considering in-licensing a product in a therapy area new to the company.
The company had conducted initial due diligence, however they wanted to ensure they had fully evaluated the relevant market factors, before finalising the in-licensing commercial arrangements.
With limited internal knowledge of the therapy area, the company commissioned CHASE to supplement their initial work.
Over a month, CHASE carried out a market analysis for the company including;
CHASE’s report confirmed that the product had strong growth potential and included detailed recommendations on the pricing and resource levels that would be required for a successful launch.
With this knowledge the company was able to advance the in-licensing negotiation and seek terms that would support the recommended UK pricing strategy.
Take a look through our other case studies in the life-sciences industry.